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itius, Altius, Fortius
The Olympic Motto:
wifter, Higher, Stronger)*
amela S. Douglas, MD, FACC
adison, Wisconsin
n this Olympic year, as since time immemorial, we are
ascinated with the achievements of athletes. As cardiolo-
ists, we have a special interest in the athlete’s heart, how it
dapts to exercise training, what its limits are, and whether
xercise can cause harm. In the 1950s, Paul Dudley White
erformed an autopsy on Clarence DeMar, a perennial
oston Marathon winner, and noted an enlarged heart and
rteries. As new imaging techniques such as echocardiog-
aphy have confirmed that cardiac structural changes are an
ntegral part of the response to exercise, investigators and
linicians alike have struggled to differentiate the physio-
ogic effects of exercise training from the pathologic entities
f hypertrophic and dilated cardiomyopathy.
A separate but related area of investigation seeks to define
he upper limits of cardiac adaptation to the physiologic
timulus of exercise. Recently, a genetic component to physi-
logic hypertrophy has been confirmed, revealing that the
gain of function” model of the athlete’s heart is influenced by
enetics as well as environmental factors such as the type
nd duration of training (1,2).
See page 144
In this issue of the Journal, Abergel et al. (3) shed light on
oth these concerns through an echocardiographic study of
large number of elite professional cyclists participating in
he Tour de France. They noted marked left ventricular (LV)
ilation in a subset of athletes, with more modest increases in
all thickness. Their findings confirm previous studies of
lympians (4), ultradistance triathletes (5), and others: endur-
nce athletes often have substantial cardiac dilation coupled
ith modestly increased wall thickness. Although cardiac
emodeling lies within the range of normal for most athletes, it
esults in mild eccentric hypertrophy in many.
Although Abergel et al. (3) have carefully used a contem-
oraneous control group to define the normal ranges of LV
imensions and mass, for the important entity of eccentric
emodeling, they use a single cut point (0.44), whose
erivation is unreferenced. As a cut point, 0.44 defines the
imit of concentric, not eccentric, remodeling. In fact, the
ean value for relative wall thickness in controls is 0.342,
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Section of Cardiovascular Medicine, Department of Medicine, University(f Wisconsin, Madison, Wisconsin.hereas that in athletes is actually higher (less eccentric
eometry) at 0.354 (p  0.06). Clearly the definition of
normal” will dramatically alter results; the use of the Abergel
t al. (3) controls suggests far less eccentric remodeling than is
laimed. Nevertheless, cavity diameter was increased to a more
arked degree than has previously been reported.
Among the influences creating the structural adaptations
n athlete’s heart, foremost is undoubtedly the physical
raining itself. In this respect, cycling is a combination of
erobic and resistance training. Even among cyclists, train-
ng for the Tour de France is notable for its endurance and,
ence, the sheer volume of training required. Furthermore,
f 29 sports studied in 1,309 Olympic athletes (6), cycling
ad the most marked impact on athletic “remodeling.”
hus, the Abergel et al. (3) findings can justifiably be
onsidered to identify the upper limits of normal of cardiac
xercise adaptation in any sport.
Other environmental factors may affect cardiac adapta-
ion to exercise, including the overall duration of training,
hase of training, hydration, time since last exercise bout,
nd so on. A prominent concern is the use of performance-
nhancing drugs, including but not limited to anabolic
teroids, growth hormones, erythropoietin, and stimu-
ants—which are notoriously prevalent in the cycling world
nd whose long-term cardiac effects are incompletely studied
7). The impact of such substances upon the findings of
bergel et al. (3) cannot be known, but they may have
ontributed to the more extreme findings than previously
eported. Furthermore, increased use over time may have been
esponsible for the more marked changes in the 1998 cohort.
Regardless of the causal stimuli, much has been written
bout differentiating athlete’s heart from hypertrophic car-
iomyopathy (HCM) (8). Discriminating features include
amily and athletic history, cavity size, magnitude and
symmetry of hypertrophy (no athletes had a wall thickness
15 mm or septal/posterior wall ratio of 1.5) and,
erhaps most distinctively, diastolic function. The impor-
ance and power of diastolic function measurement in
creening for HCM was highlighted recently when tissue
oppler was used successfully to identify HCM carriers
ven in the absence of any other evidence of pathologic
henotype, including any increase in wall thickness (9).
In addition to differentiation from concomitant patho-
ogic hypertrophy, the magnitude of LV dilation observed
y Abergel et al. (3) overlaps with that observed in cardio-
yopathy. Of even greater concern is the reduced ejection
raction noted in 12% of athletes with extreme cavity
ilation, although most of these were not unexpectedly low,
iven calculated afterload. Even if asymptomatic cardiomy-
pathy can be excluded, similar degrees of dilation predict
uture development of cardiomyopathy, even in the absence
f ischemic syndromes (10). Although less attention has
een paid to the differentiation of an athlete’s heart from an
arly stage of dilated cardiomyopathy than from HCM
perhaps because of the clear relationship between sudden
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July 7, 2004:150–1 Editorial Commenteath and exertion in this disease), LV dilation is probably no
ess relevant a target for preparticipation screening than wall
hickness. This is also an important area for future research.
Most studies of the athletic heart are cross-sectional—
ew provide serial data. In this respect, the more marked LV
ilation observed by Abergel et al. (3) in the same athletes
n 1998 compared with three years earlier is of substantial
nterest. It is possible that some of the training or environ-
ental stimuli to physiologic hypertrophy were more
arked, but the issue of possible harm from high-intensity,
rolonged exercise training and competition is raised. In
his respect, even single episodes of prolonged exercise result
n transient decreases in LV systolic function, along with
ow-level troponin leakage, suggesting that myocardial in-
ury can result from exercise (11,12). It is easy to imagine
hat repeated “minor injuries” of this type might eventually
ause significant pathology—perhaps in the form of the
xcessive chamber dilation noted by Abergel et al. (3).
lthough it is of course beyond the scope of the Abergel et
l. paper (3) to identify any causal relationship, it is hard to
gnore the possibility that extreme amounts of exercise may
ause harm. Fortunately, because few individuals train and
ompete at the extraordinary level of Tour de France
yclists, its relevance is probably limited. It appears that,
ven with exercise, one of the most powerful strategies for
ood health and longevity is moderation.
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